UCB's Global Corporate Website
Welcome to UCB in the United States



UCB Announces BRIVIACT® (brivaracetam) CV Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and Older



Improving Diversity in Dermatology

This August, the theme for Psoriasis Action Month is ‘All of Us.’ UCB is joining the National Psoriasis Foundation to shine light on the condition’s impact on diverse populations, and celebrate the diversity and inclusivity of the psoriasis community. Read more from Rhonda Peebles, Head of U.S. Dermatology, as she shares her thoughts on racial inequities in dermatology and the steps UCB is taking to move the equity needle forward. 



New Two-Year Data Showed Bimekizumab Maintained High Levels of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis



“All of Us” vs. Psoriasis

As part of Psoriasis Action Month, Camille Lee, Head of U.S. Immunology at UCB, shares how UCB is helping find and bridge gaps in psoriatic disease care.